AstraZeneca's Imfinzi Improves Survival in Lung Cancer Study

AstraZeneca PLC. AZNannounced that a phase III PACIFIC study evaluating its oncology candidate, Imfinzi (durvalumab), for an early stage lung cancer indication met its second primary endpoint of overall survival (OS). The study was conducted on patients with locally-advanced, unresectable (stage III) non-small cell lung cancer (NSCLC), whose disease has not progressed following platinum-based chemotherapy concurrent with radiation therapy (CRT).

Please note that Imfinzi was approved in the United States for this indication in February this year based on positive progression free survival data